Analog of somatostatin vapreotide exhibits biological effects in vitro via interaction with neurokinin-1 receptor

NeuroImmunoModulation

Volumn 20, Issue 5, 2013, Pages 247-255

  Spitsin, Sergei ^a   Tuluc, Florin ^a,b   Meshki, John ^a   Ping Lai, Jian ^a   Tustin Iii, Richard ^a   Douglas, Steven D ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cyanamid 154806; HIV; Neurokinin 1 receptor; Somatostatin; Somatostatin 2 receptor; Substance P; Vapreotide

Indexed keywords

APREPITANT; CALCIUM ION; EARLY GROWTH RESPONSE FACTOR 1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROKININ 1 RECEPTOR; SUBSTANCE P; VAPREOTIDE;

ARTICLE; ASTROCYTOMA CELL; ASTROCYTOMA CELL LINE; BIOLOGICAL ACTIVITY; CALCIUM CELL LEVEL; CYTOKINE PRODUCTION; DRUG ANTAGONISM; ENZYME ACTIVATION; GENE EXPRESSION; HEK293 CELL LINE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMEDIATE EARLY GENE; IMMORTALIZED CELL LINE; IN VITRO STUDY; MACROPHAGE; MONOCYTE; MONOCYTE DERIVED MACROPHAGE; ONCOGENE C FOS; PRIORITY JOURNAL; PROTEIN INTERACTION; VIRUS REPLICATION; CONTROLLED STUDY; DOSE RESPONSE; KIDNEY CELL; NONHUMAN; PROTEIN EXPRESSION;

ANALGESICS; CALCIUM; CELL LINE; CHEMOKINE CCL2; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE EXPRESSION REGULATION; HUMANS; MACROPHAGES; MORPHOLINES; NEUROKININ-1 RECEPTOR ANTAGONISTS; NF-KAPPA B; RECEPTORS, NEUROKININ-1; RECEPTORS, SOMATOSTATIN; SIGNAL TRANSDUCTION; SOMATOSTATIN; SUBSTANCE P; TRANSFECTION;

EID: 84880994702     PISSN: 10217401     EISSN: 14230216     Source Type: Journal    
DOI: 10.1159/000350468     Document Type: Article

References (56)

1. Tuluc F, Lai JP, Kilpatrick LE, Evans DL, Douglas SD: Neurokinin 1 receptor isoforms and the control of innate immunity. Trends Immunol 2009; 30: 271-276.
2. Douglas SD, Leeman SE: Neurokinin-1 receptor: functional significance in the immune system in reference to selected infections and inflammation. Ann NY Acad Sci 2011; 1217: 83-95.
3. Fong TM, Anderson SA, Yu H, Huang RR, Strader CD: Differential activation of intracellular effector by two isoforms of human neurokinin-1 receptor. Mol Pharmacol 1992; 41: 24-30.
4. Ho WZ, Lai JP, Zhu XH, Uvaydova M, Douglas SD: Human monocytes and macrophages express substance P and neurokinin-1 receptor. J Immunol 1997; 159: 5654-5660.
5. Lai JP, Douglas SD, Ho WZ: Human lymphocytes express substance P and its receptor. J Neuroimmunol 1998; 86: 80-86.
6. Lai JP, Zhan GX, Campbell DE, Douglas SD, Ho WZ: Detection of substance P and its receptor in human fetal microglia. Neuroscience 2000; 101: 1137-1144.
7. Li Y, Douglas SD, Ho W: Human stem cells express substance P gene and its receptor. J Hematother Stem Cell Res 2000; 9: 445-452.
8. Li Y, Douglas SD, Pleasure DE, Lai J, Guo C, Bannerman P, Williams M, Ho W: Human neuronal cells (NT2-N) express functional substance P and neurokinin-1 receptor coupled to MIP-1 beta expression. J Neurosci Res 2003; 71: 559-566.
9. Ho WZ, Lai JP, Li Y, Douglas SD: HIV enhances substance P expression in human immune cells. FASEB J 2002; 16: 616-618.
10. Ho WZ, Douglas SD: Substance P and neurokinin-1 receptor modulation of HIV. J Neuroimmunol 2004; 157: 48-55.
11. Monaco-Shawver L, Schwartz L, Tuluc F, Guo CJ, Lai JP, Gunnam SM, Kilpatrick LE, Banerjee PP, Douglas SD, Orange JS: Substance P inhibits natural killer cell cytotoxicity through the neurokinin-1 receptor. J Leukoc Biol 2011; 89: 113-125.
12. Sudduth-Klinger J, Schumann M, Gardner P, Payan DG: Functional and immunological responses of Jurkat lymphocytes transfected with the substance P receptor. Cell Mol Neurobiol 1992; 12: 379-395.
13. Seabrook GR, Fong TM: Thapsigargin blocks the mobilisation of intracellular calcium caused by activation of human NK1 (long) receptors expressed in Chinese hamster ovary cells. Neurosci Lett 1993; 152: 9-12.
14. Lai JP, Cnaan A, Zhao H, Douglas SD: Detection of full-length and truncated neurokinin-1 receptor mRNA expression in human brain regions. J Neurosci Methods 2008; 168: 127-133.
15. Lieb K, Fiebich BL, Berger M, Bauer J, Schulze-Osthoff K: The neuropeptide substance P activates transcription factor NF-kappa B and kappa B-dependent gene expression in human astrocytoma cells. J Immunol 1997; 159: 4952-4958.
16. Marriott I, Bost KL: IL-4 and IFN-gamma upregulate substance P receptor expression in murine peritoneal macrophages. J Immunol 2000; 165: 182-191.
17. Khan MM, Douglas SD, Benton TD: Substance P-neurokinin-1 receptor interaction upregulates monocyte tissue factor. J Neuroimmunol 2012; 242: 1-8.
18. Lai JP, Lai S, Tuluc F, Tansky MF, Kilpatrick LE, Leeman SE, Douglas SD: Differences in the length of the carboxyl terminus mediate functional properties of neurokinin-1 receptor. Proc Natl Acad Sci USA 2008; 105: 12605-12610.
19. Koon HW, Zhao D, Zhan Y, Simeonidis S, Moyer MP, Pothoulakis C: Substance P-stimulated interleukin-8 expression in human colonic epithelial cells involves protein kinase Cdelta activation. J Pharmacol Exp Ther 2005; 314: 1393-1400.
20. Ramnath RD, Sun J, Bhatia M: Role of calcium in substance P-induced chemokine synthesis in mouse pancreatic acinar cells. Br J Pharmacol 2008; 154: 1339-1348.
21. Lieb K, Schaller H, Bauer J, Berger M, Schulze-Osthoff K, Fiebich BL: Substance P and histamine induce interleukin-6 expression in human astrocytoma cells by a mechanism involving protein kinase C and nuclear factor-IL-6. J Neurochem 1998; 70: 1577-1583.
22. Al-Sarraj A, Thiel G: Substance P induced biosynthesis of the zinc finger transcription factor EGR-1 in human glioma cells requires activation of the epidermal growth factor receptor and of extracellular signal-regulated protein kinase. Neurosci Lett 2002; 332: 111-114.
23. Luo W, Sharif TR, Houghton PJ, Sharif M: CGP 41251 and tamoxifen selectively inhibit mitogen-activated protein kinase activation and c-Fos phosphoprotein induction by substance P in human astrocytoma cells. Cell Growth Differ 1997; 8: 1225-1240.
24. Choi SS, Lee HK, Shim EJ, Kwon MS, Seo YJ, Lee JY, Suh HW: Alterations of c-Fos mRNA expression in hypothalamic-pituitary-adrenal axis and various brain regions induced by intrathecal single and repeated substance P administrations in mice. Arch Pharm Res 2004; 27: 863-866.
25. Spitznagel H, Baulmann J, Blume A, Unger T, Culman J: c-Fos expression in the rat brain in response to substance P and neurokinin B. Brain Res 2001; 916: 11-21.
26. Ho WZ, Kaufman D, Uvaydova M, Douglas SD: Substance P augments interleukin-10 and tumor necrosis factor-alpha release by human cord blood monocytes and macrophages. J Neuroimmunol 1996; 71: 73-80.
27. Lai JP, Ho WZ, Zhan GX, Yi Y, Collman RG, Douglas SD: Substance P antagonist (CP-96,345) inhibits HIV-1 replication in human mononuclear phagocytes. Proc Natl Acad Sci USA 2001; 98: 3970-3975.
28. Ho WZ, Cnaan A, Li YH, Zhao H, Lee HR, Song L, Douglas SD: Substance P modulates human immunodeficiency virus replication in human peripheral blood monocyte-derived macrophages. AIDS Res Hum Retroviruses 1996; 12: 195-198.
29. Wang X, Douglas SD, Lai JP, Tuluc F, Tebas P, Ho WZ: Neurokinin-1 receptor antagonist (aprepitant) inhibits drug-resistant HIV-1 infection of macrophages in vitro. J Neuroimmune Pharmacol 2007; 2: 42-48.
30. Blum AM, Metwali A, Mathew RC, Elliott D, Weinstock JV: Substance P and somatostatin can modulate the amount of IgG2a secreted in response to schistosome egg antigens in murine schistosomiasis mansoni. J Immunol 1993; 151: 6994-7004.
31. Blum AM, Metwali A, Cook G, Mathew RC, Elliott D, Weinstock JV: Substance P modulates antigen-induced, IFN-gamma production in murine schistosomiasis mansoni. J Immunol 1993; 151: 225-233.
32. Betoin F, Advenier C, Fardin V, Wilcox G, Lavarenne J, Eschalier A: In vitro and in vivo evidence for a tachykinin NK1 receptor antagonist effect of vapreotide, an analgesic cyclic analog of somatostatin. Eur J Pharmacol 1995; 279: 241-249.
33. Meshki J, Douglas SD, Hu M, Leeman SE, Tuluc F: Substance P induces rapid and transient membrane blebbing in U373MG cells in a p21-activated kinase-dependent manner. PLoS One 2011; 6:e25332.
34. Hassan NF, Campbell DE, Douglas SD: Purification of human monocytes on gelatin-coated surfaces. J Immunol Methods 1986; 95: 273-276.
35. Hassan NF, Cutilli JR, Douglas SD: Isolation of highly purified human blood monocytes for in vitro HIV-1 infection studies of monocyte/macrophages. J Immunol Methods 1990; 130: 283-285.
36. Petrak D, Memon SA, Birrer MJ, Ashwell JD, Zacharchuk CM: Dominant negative mutant of c-Jun inhibits NF-AT transcriptional activity and prevents IL-2 gene transcription. J Immunol 1994; 153: 2046-2051.
37. Snider RM, Constantine JW, Lowe JA 3rd, Longo KP, Lebel WS, Woody HA, Drozda SE, Desai MC, Vinick FJ, Spencer RW: A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 1991; 251: 435-437.
38. Grynkiewicz G, Poenie M, Tsien RY: A new generation of Ca 2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-3450.
39. Lai JP, Yang JH, Douglas SD, Wang X, Riedel E, Ho WZ: Quantification of CCR5 mRNA in human lymphocytes and macrophages by real-time reverse transcriptase PCR assay. Clin Diagn Lab Immunol 2003; 10: 1123-1128.
40. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001; 25: 402-408.
41. Buscail L, Esteve JP, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll AM, Bell GI, Schally AV, Vaysse N, Susini C: Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 1995; 92: 1580-1584.
42. Chen P, Douglas SD, Meshki J, Tuluc F: Neurokinin 1 receptor mediates membrane blebbing and sheer stress-induced microparticle formation in HEK293 cells. PLoS One 2012; 7:e45322.
43. Meshki J, Douglas SD, Lai JP, Schwartz L, Kilpatrick LE, Tuluc F: Neurokinin 1 receptor mediates membrane blebbing in HEK293 cells through a RHO/RHO-associated coiledcoil kinase-dependent mechanism. J Biol Chem 2009; 284: 9280-9289.
44. Douglas SD, Lai JP, Tuluc F, Schwartz L, Kilpatrick LE: Neurokinin-1 receptor expression and function in human macrophages and brain: perspective on the role in HIV neuropathogenesis. Ann NY Acad Sci 2008; 1144: 90-96.
45. Chernova I, Lai JP, Li H, Schwartz L, Tuluc F, Korchak HM, Douglas SD, Kilpatrick LE: Substance P (SP) enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor (NK1R). J Leukoc Biol 2009; 85: 154-164.
46. Elliott DE, Li J, Blum AM, Metwali A, Patel YC, Weinstock JV: SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-gamma release. Eur J Immunol 1999; 29: 2454-2463.
47. Booth CE, Kirkup AJ, Hicks GA, Humphrey PP, Grundy D: Somatostatin SST(2) receptormediated inhibition of mesenteric afferent nerves of the jejunum in the anesthetized rat. Gastroenterology 2001; 121: 358-369.
48. Li Y, Douglas SD, Song L, Sun S, Ho WZ: Substance P enhances HIV-1 replication in latently infected human immune cells. J Neuroimmunol 2001; 121: 67-75.
49. Guo CJ, Lai JP, Luo HM, Douglas SD, Ho WZ: Substance P up-regulates macrophage inflammatory protein-1beta expression in human T lymphocytes. J Neuroimmunol 2002; 131: 160-167.
50. Manak MM, Moshkoff DA, Nguyen LT, Meshki J, Tebas P, Tuluc F, Douglas SD: Anti-HIV-1 activity of the neurokinin-1 receptor antagonist aprepitant and synergistic interactions with other antiretrovirals. AIDS 2010; 24: 2789-2796.
51. Vinet-Oliphant H, Alvarez X, Buza E, Borda JT, Mohan M, Aye PP, Tuluc F, Douglas SD, Lackner AA: Neurokinin-1 receptor (NK1-R) expression in the brains of SIV-infected rhesus macaques: implications for substance P in NK1-R immune cell trafficking into the CNS. Am J Pathol 2010; 177: 1286-1297.
52. Douglas SD, Cnaan A, Lynch KG, Benton T, Zhao H, Gettes DR, Evans DL: Elevated substance P levels in HIV-infected women in comparison to HIV-negative women. AIDS Res Hum Retroviruses 2008; 24: 375-378.
53. Douglas SD, Ho WZ, Gettes DR, Cnaan A, Zhao H, Leserman J, Petitto JM, Golden RN, Evans DL: Elevated substance P levels in HIVinfected men. AIDS 2001; 15: 2043-2045.
54. Wang X, Douglas SD, Song L, Wang YJ, Ho WZ: Neurokinin-1 receptor antagonist (aprepitant) suppresses HIV-1 infection of microglia/macrophages. J Neuroimmune Pharmacol 2008; 3: 257-264.
55. Ansari AW, Heiken H, Meyer-Olson D, Schmidt RE: CCL2: a potential prognostic marker and target of anti-inflammatory strategy in HIV/AIDS pathogenesis. Eur J Immunol 2011; 41: 3412-3418.
56. Palmer S, Wiegand AP, Maldarelli F, Bazmi H, Mican JM, Polis M, Dewar RL, Planta A, Liu S, Metcalf JA, Mellors JW, Coffin JM: New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol 2003; 41: 4531-4536.